Clinical trial · Observational
A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Nimotuzumab Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Resectable Pancreatic Cancer: a Propensity Score Matching Analysis
NCT06363084CI-TRIAL-00075990completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial is a retrospective, observational study, patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Resectable Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nimotuzumab | Drug | Nimotuzumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- study arm
- description
- Nimotuzumab plus adjuvant chemotherapy
- interventionNames
- Drug: Nimotuzumab
- label
- control arm
- description
- adjuvant chemotherapy alone (without Nimotuzumab)
Primary outcomes (1)
- measure
- overall survival (OS）
- timeFrame
- approximately 84 months
- description
- The primary endpoint is overall survival (OS), defined as the time from the start of surgery to the date of death due to any cause.
Secondary outcomes (2)
- measure
- disease-free survival (DFS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age≥18 years old, gender is not limited; * Confirmed by histopathological or cytological diagnosis of pancreatic cancer; * Underwent surgical resection of the pancreas for non-metastatic pancreatic cancer (including resectable/borderline resectable pancreatic cancer, or locally advanced pancreatic cancer); * Received Nimotuzumab plus adjuvant chemotherapy or adjuvant chemotherapy alone after surgery. Exclusion Criteria: * Patients with other primary malignancies other than pancreatic cancer; * Evidence of recurrence or distant metastasis before surgery * Received immunotherapy drugs (such as PD-1 inhibitors, etc.) used during adjuvant therapy, or proprietary Chinese medicines with anti-tumor indications, or hyperthermia, targeted therapy drugs other than nimotuzumab; * Key information is missing (e.g., primary endpoint data were not available).
References
Publications (0)
Data not yet available
No reference posted for this study.